Mineralys Therapeutics, Inc.
MLYS
$25.64
-$0.45-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 17.58% | 51.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 442.66% | 18.44% | |||
| Operating Income | -442.66% | -18.44% | |||
| Income Before Tax | -512.80% | -22.04% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -512.80% | -22.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -512.80% | -22.04% | |||
| EBIT | -442.66% | -18.44% | |||
| EBITDA | -442.72% | -18.47% | |||
| EPS Basic | -499.14% | -18.67% | |||
| Normalized Basic EPS | -499.16% | -18.67% | |||
| EPS Diluted | -499.14% | -18.67% | |||
| Normalized Diluted EPS | -499.16% | -18.67% | |||
| Average Basic Shares Outstanding | 2.28% | 2.84% | |||
| Average Diluted Shares Outstanding | 2.28% | 2.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||